PYC THERAPEUTICS LIMITED — Director's Dealing 2020

Nov 9, 2020

10 November 2020

Final Director's Interests Notice - Appendix 3Z

PYC Therapeutics Limited (the 'Company') submits the following Appendix 3Z – Final Director's Interests Notice, in relation to the retirement of Mr Douglas Huey.

This ASX announcement was approved and authorised for release by Rohan Hockings CEO of PYC Therapeutics Limited.

ENDS For further information, please contact:

INVESTORS Rohan Hockings CEO info@pyctx.com

About PYC Therapeutics

PYC Therapeutics Limited (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome 'the delivery challenge' and provide access for a wide range of potent and precise drug 'cargoes' to the 'undruggable genome' – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

Tel: +61 8 6151 0994 pyctx.com PYC Therapeutics Limited

ACN 098 391 961

Appendix 3Z

Rule 3.19A.3

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

	Name of entity	PYC Therapeutics Limited
ACN	098 391 961

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	DOUGLAS HUEY
Date of last notice	12 February 2020
Date that director ceased to be director	6 November 2020

Part 1 – Director's relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

6,666,667 unlisted options exercisable by the payment of $0.063 on or before 28 February 2023.

+ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interestNote: Provide details of the circumstances giving rise tothe relevant interest	Number & class of securities
Nil

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
No. and class of securities to whichinterest relates	N/A

+ See chapter 19 for defined terms.